Short answer
Keros Therapeutics, Inc. (KROS) filed its Q1 2026 10-Q quarterly report on May 14, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $367,000 (down 99.8% year over year) with net income of −$24M.
Q1 2026 key financials · XBRL
- Revenue
- $367,000
- −99.8% YoY
- Net income
- −$24M
- −116.0% YoY
- Operating margin
- -7051.0%
- EPS (diluted)
- −$1.21
- −133.4% YoY
Source: XBRL data from the Keros Therapeutics, Inc. (KROS) Q1 2026 10-Q on SEC EDGAR. USD.
Keros Therapeutics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0.4M, down $210.9M YoY from $211.2M, following lower Takeda license revenue
- Operating loss $25.9M vs $152.0M income YoY; net loss $23.7M vs $148.5M income
- Best product-line trend: rinvatercept R&D $2.7M, up $1.1M YoY; elritercept R&D $3K, down $18.9M
- Cash and equivalents $281.5M at March 31, 2026; no ATM shares sold during the quarter
- Continued operating losses and negative operating cash flows expected; Phase 2 rinvatercept DMD trial planned for third quarter 2026
Risk Factors
- Net loss $23.7 million and accumulated deficit $505.5 million as of March 31, 2026
- Cash $281.5 million, expected to fund operations into first half of 2028
- Rinvatercept Phase 2 expansion into Duchenne muscular dystrophy and ALS increasing development spending
- Cibotercept TROPOS trial terminated after pericardial effusion adverse events identified in January 2025
- Future funding risk from reliance on equity offerings, collaborations, and other financing sources
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Keros Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.